Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2010

View Archived Issues

SYN-115 enhances effects of levodopa in Parkinson's disease patients

FDA approves labeling update for Tibotec's Prezista for HIV-1

IND to test androxal in men with type 2 diabetes and hypogonadism now effective

Gilead reports fourth quarter 2009 results

PROSPER data indicate no effect of pravastatin sodium on cognitive decline in the elderly

Antitumor activity of GMX-1777 plus radiotherapy seen in head and neck cancer models

Possible correlation between gender and genotype reported in pediatric onset of CD

AstraZeneca discloses novel Nav1.7 voltage-gated sodium channel blockers

Princeton University claims quorum-sensing signaling modulators for bacterial infections

Boehringer Ingelheim claims new chemokine CCR10 receptor antagonists

Labopharm receives FDA approval for Oleptro for major depressive disorder

Pharmasset describes new prodrugs of NS5B inhibitors

New antiepileptic agents described by University of North Carolina at Chapel Hill

FDA requests additional information for Protalix's taliglucerase alfa NDA

Onyx agrees with the FDA on a SPA for planned phase III carfilzomib trial

Vantia's VA-106483 enters phase IIb trial for nocturia

FDA approves Xiaflex for debilitating hand disease

Recordati receives European approval for silodosin for BPH

NeuroSearch presents topline results from phase III Huntexil study

Evotec and Vifor sign agreement to identify preclinical candidate in anemia

Spectrum and TopoTarget sign agreement for HDAC inhibitor belinostat

FDA accepts for formal review Javelin's NDA for NSAID Dyloject

EMEA issues scientific advice to Hybrigenics for clinical development of inecalcitol

Seattle and Millennium initiate phase I combination clinical trial of brentuximab

Oxytocin attenuates methamphetamine self-administration in rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...